The LODH Immunology Fund is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank.
The LODH Immunology Fund is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank. Approximately 20% of the assets of the fund are invested in privately held biotech companies.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
May 12, 2009
NovImmune
|
Series Unknown | $54.80M | Biotechnology | — |
Jun 1, 2006
NovImmune
|
Series B | $46M | Biotechnology | — |
May 14, 2002
ESBATech
|
Series A | Fr14.50M | Biotechnology | Yes |
Sep 27, 2001
7TM Pharma
|
Series A | $15M | Biotechnology | — |
Jun 13, 2000
Genmab
|
Series Unknown | $40.50M | Biotechnology | — |